「T-Cell」の共起表現(1語右で並び替え)

「T-Cell」の共起表現一覧(1語右で並び替え)

T-Cell

1語右で並び替え

該当件数:75件

Thus pimecrolimus inhibits T-cell activation by inhibiting the synthesis and rel
nd T cells encounters a programmed change upon T-cell activation, which predominantly produces full-
are also widely accepted as the initiators of T-cell activation.
hysiologic ligand-receptor complex involved in T-cell activation.
bition of B7-CTLA-4-mediated downregulation of T-cell activation; subsequently, B7.1 or B7.2 may int
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia.
n October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lympho
Increasing T-cell age reduces effector activity but preserves pr
iagnosed with lymphoblastic leukemia/lymphoma ( T-cell ALL), a complex form of cancer targeting the l
amily that is also called Interferon-inducible T-cell alpha chemoattractant (I-TAC) and Interferon-g
ant developmental signals from IL-7 and IL-15, T-cell and NK cell populations respectively fail to d
it is known to be a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.
n tyrosine kinases following activation of the T-cell antigen receptor (TCR) signal transduction pat
ins spontaneously distatch from the TCR of the T-cell, because of weak binding affinities (monomeric
structure of CD28 was obtained in 2005 by the T-cell biology group at the University of Oxford.
CXCL9 is a T-cell chemoattractant, which is induced by IFN-γ.
He showed that the T-cell co-receptors CD4 (also the receptor for the hu
Inducible T-cell costimulator is a protein that in humans is en
ndent manner, indicating that gliadin specific T-cell could present these antigens to the immune sys
with ionomycin, can also be used to stimulate T-cell cytokine production, and is used in protocols
fic function in the mechanism or regulation of T-cell cytolytic activity.
results in a cascade of signals important for T-cell development within the thymus and survival wit
L-7 receptor exhibit thymic atrophy, arrest of T-cell development at the double positive stage, and
ntibody, chemically linked Fab and bi-specific T-cell engager (bottom row).
Bi-specific T-cell engagers employ a smilar mechanism of action w
r NF-kappaB, and on development of bi-specific T-cell engagers for therapy of cancer.
nce, showing the overlapping of 3 varieties of T-cell epitope.
g this bond transglutaminase becomes linked to T-cell epitopes on gliadin.
stable in human blood serum and do not contain T-cell epitopes.
-6 causes an IL-10-dependent inhibition of CD4 T-cell expansion and function by up-regulating PD-1 l
TA causes an IL-10-dependent inhibition of CD4 T-cell expansion and function by up-regulating PD-1 l
This receptor can activate T-cell factor signaling.
BTLA-HVEM complexes negatively regulate T-cell immune responses.
iology at Yale School of Medicine, focusing on T-cell immunity in West Nile Virus, publishing severa
ding of the intracellular signals that control T-cell immunity.
mutation in this gene has been correlated with T-cell immunodeficiency, the skin disorder congenital
loepiphyseal dysplasia, renal dysfunction, and T-cell immunodeficiency.
However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis
here it appears to mediate aspects of B-cell - T-cell interaction.
This technology combines a current T-cell isolation method with the Strep-tag technology
ing HTLV-I induced diseases like ATL the adult T-cell leukemia and HMS/TSP like neurological disorde
viruses, initially as a means of understanding T-cell leukemia and other cancers, which may be cause
roto-oncogene implicated in the development of T-Cell Leukemias.
ed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial c
II trials for multiple myeloma and peripheral T-cell lymphoma are still recruiting.
, he was diagnosed with enteropathy-associated T-cell lymphoma in January 2009 and died on 24 June 2
dministration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).
tment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at
on from the FDA for the treatment of cutaneous T-cell lymphoma, and orphan drug status from the FDA
inent in a rare cancer, enteropathy associated T-cell lymphoma.
Hence, expression of CXCL13 in T-cell lymphomas, such as Angioimmunoblastic T-cell L
in reference to the Tax1 protein of the Human T-cell Lymphotropic Virus (HTLV)which was used to dis
found the drug caused many stage IV cutaneous T-cell lympomas to regress or stabilize extending pat
CD5 was used as a T-cell marker until monoclonal antibodies against CD3
sis fungoides, but is frequently lost in other T-cell neoplasms.
stablishing a specific interaction between the T-cell of interest and a molecule that is conjugated
The gene is expressed in B-cell but not T-cell or myeloid cell lines.
Temporary depletion of the T-cell population at the time of the transplant also
mily with strong homology to the Suppressor of T-cell receptor signaling-1 (Sts-1 PGM) protein.
ity hypothesis states that the affinity of the T-cell receptor for the MHC:peptide complex and the d
T-cell receptor zeta, together with T-cell receptor a
transmit signals from the B-Cell receptor and T-Cell receptor.
ith a Tyrosine phosphorylated Peptide from the T-cell Receptor.
unoglobulin light and heavy chains; in several T-cell receptors such as CD2 (Cluster of Differentiat
It also supports signaling from T-cell receptors.
ass I and II complex molecules, and in various T-cell receptors.
o diagnose SCID in newborns through the use of T-cell recombinant excision circles.
may offer new strategies in clinical and basic T-cell research.
They are activated and control T-cell responses to foreign pathogens, transplants an
For the T-cell signal, see T helper cell#Verification (Signal
T-cell surface glycoprotein CD3 zeta chain also known
T-cell surface glycoprotein CD1e, membrane-associated
It has also been called T-cell surface antigen T11/Leu-5, LFA-2, LFA-3 recept
T-cell surface antigen CD2 IPR013285
as to be custom made for each antigen specific t-cell that one desires to detect.